Bermejo-Guerrero, Laura, de Fuenmayor-Fernández de la Hoz, Carlos Pablo, Guerrero-Molina, María Paz et al. · Journal of clinical medicine · 2023 · DOI
This study tested whether a blood marker called GDF-15 could help doctors tell the difference between ME/CFS and a rare condition called primary mitochondrial myopathy (PMM), which affects how cells produce energy. Both conditions cause fatigue and exercise intolerance that can look very similar, but PMM requires different treatment. The researchers found that GDF-15 levels were very good at distinguishing between these two conditions, which could help patients get the right diagnosis faster without needing extensive genetic testing or muscle biopsies.
Many ME/CFS patients undergo extensive and sometimes invasive testing to rule out mitochondrial disease, which causes significant burden and cost. A simple, accurate blood test could reduce unnecessary investigations, accelerate diagnosis, and help identify the subset of fatigued patients who actually have treatable mitochondrial disorders. This distinction is clinically important because mitochondrial myopathy requires specific management approaches.
This study does not prove that GDF-15 is elevated in PMM due to mitochondrial dysfunction specifically, only that it correlates with PMM diagnosis. The small sample size limits confidence in the true sensitivity and specificity in broader populations. Additionally, the study does not establish whether GDF-15 could discriminate PMM from other genetic or metabolic conditions that weren't included in this cohort.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Contribute
Private, reviewed by a human. Not a public comment thread.